UA90521C2 - Фармацевтична композиція, що містить симвастатин і езетиміб - Google Patents

Фармацевтична композиція, що містить симвастатин і езетиміб

Info

Publication number
UA90521C2
UA90521C2 UAA200714923A UAA200714923A UA90521C2 UA 90521 C2 UA90521 C2 UA 90521C2 UA A200714923 A UAA200714923 A UA A200714923A UA A200714923 A UAA200714923 A UA A200714923A UA 90521 C2 UA90521 C2 UA 90521C2
Authority
UA
Ukraine
Prior art keywords
ezetimibe
simvastatin
pharmaceutical composition
oxygen
present
Prior art date
Application number
UAA200714923A
Other languages
English (en)
Russian (ru)
Inventor
Вєсна Крошельй
Рената Лаксе
Ребека Топорісіч
Йоже Кастеліч
Original Assignee
Крка Товарна Здравіл, Д.Д. Ново Мєсто
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34937786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA90521(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Крка Товарна Здравіл, Д.Д. Ново Мєсто filed Critical Крка Товарна Здравіл, Д.Д. Ново Мєсто
Publication of UA90521C2 publication Critical patent/UA90521C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Preparations (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

Винахід належить до галузі фармацевтичної технології і, зокрема, до нових лікарських форм лікарських засобів, що містять як активні інгредієнти симвастатин і езетиміб або їхні фармацевтично прийнятні солі та не містять стабілізаторів, зокрема антиоксидантів.
UAA200714923A 2005-07-06 2006-06-30 Фармацевтична композиція, що містить симвастатин і езетиміб UA90521C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014680A EP1741427A1 (en) 2005-07-06 2005-07-06 Pharmaceutical composition comprising simvastatin and ezetimibe
PCT/EP2006/006369 WO2007003365A1 (en) 2005-07-06 2006-06-30 Pharmaceutical composition comprising simvastatin and ezetimibe

Publications (1)

Publication Number Publication Date
UA90521C2 true UA90521C2 (uk) 2010-05-11

Family

ID=34937786

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200714923A UA90521C2 (uk) 2005-07-06 2006-06-30 Фармацевтична композиція, що містить симвастатин і езетиміб

Country Status (17)

Country Link
US (1) US8921352B2 (uk)
EP (2) EP1741427A1 (uk)
AT (1) ATE464882T1 (uk)
CA (1) CA2614347A1 (uk)
DE (1) DE602006013821D1 (uk)
DK (1) DK1901736T3 (uk)
EA (1) EA013266B1 (uk)
ES (1) ES2341731T3 (uk)
HR (1) HRP20100282T1 (uk)
NO (1) NO340496B1 (uk)
PL (1) PL1901736T3 (uk)
PT (1) PT1901736E (uk)
RS (1) RS51338B (uk)
SI (1) SI1901736T1 (uk)
UA (1) UA90521C2 (uk)
WO (1) WO2007003365A1 (uk)
ZA (1) ZA200800111B (uk)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
EP2120882A2 (en) * 2007-02-23 2009-11-25 Krka Pharmaceutical composition containing a cholesterol absorption inhibitor
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2217214B1 (en) 2007-12-10 2017-07-19 ratiopharm GmbH Pharmaceutical formulation comprising ezetimibe
WO2009077573A2 (en) * 2007-12-17 2009-06-25 Krka, Tovarna Zdravil, D.D., Novo Mesto Suspension comprising non-micronized ezetimibe micro-particles
TR200806302A2 (tr) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite artırıcı farmasötik formülasyon.
TR200806300A2 (tr) * 2008-08-22 2010-03-22 B�Lg�� Mahmut Çözünürlük artırıcı farmasötlk formulasyon
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
WO2011019326A2 (en) * 2009-07-02 2011-02-17 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
EP2448564A2 (en) * 2009-07-02 2012-05-09 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
AR086675A1 (es) * 2011-06-14 2014-01-15 Merck Sharp & Dohme Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina
CN102266323B (zh) * 2011-08-04 2013-03-27 海南锦瑞制药股份有限公司 依折麦布和辛伐他汀组合物及其制备方法
KR102578578B1 (ko) * 2016-02-03 2023-09-14 삼성전자주식회사 암모니아수 내의 불순물 검출방법
JP7115825B2 (ja) * 2017-06-28 2022-08-09 日医工株式会社 エゼチミブ含有経口製剤及びその製造方法
JP2019014700A (ja) * 2017-07-11 2019-01-31 大原薬品工業株式会社 エゼチミブ含有口腔内崩壊錠及びその製造方法
PL425975A1 (pl) * 2018-06-19 2020-01-02 Invest Bielany Spółka Z Ograniczoną Odpowiedzialnością Złożona kompozycja farmaceutyczna do leczenia dyslipidemii i sposób jej wytwarzania
WO2022023206A1 (en) * 2020-07-27 2022-02-03 Krka, D.D., Novo Mesto Bilayer tablet comprising ezetimibe and atorvastatin
CN115227659B (zh) * 2022-08-19 2023-05-02 北京百奥药业有限责任公司 一种依折麦布辛伐他汀组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU548996B2 (en) 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
CN100509058C (zh) * 2001-01-26 2009-07-08 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗
EP1241110A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2003055467A1 (en) * 2001-12-18 2003-07-10 Synthon B.V. Simvastatin dosage forms
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
SI21400A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
AU2003259547A1 (en) 2003-07-31 2005-02-14 Hetero Drugs Limited Ezetimibe polymorphs
PL379195A1 (pl) * 2003-08-05 2006-07-24 Zentiva, A.S. Sposoby stabilizacji atorwastatyny
US20060223882A1 (en) * 2005-03-23 2006-10-05 Venkataraman Sundaram Amorphous simvastatin

Also Published As

Publication number Publication date
NO340496B1 (no) 2017-05-02
SI1901736T1 (sl) 2010-08-31
ES2341731T3 (es) 2010-06-25
EP1901736A1 (en) 2008-03-26
RS51338B (en) 2011-02-28
ATE464882T1 (de) 2010-05-15
WO2007003365A1 (en) 2007-01-11
US20080300233A1 (en) 2008-12-04
NO20080627L (no) 2008-04-02
EP1741427A1 (en) 2007-01-10
HRP20100282T1 (hr) 2010-07-31
EA013266B1 (ru) 2010-04-30
CA2614347A1 (en) 2007-01-11
DE602006013821D1 (en) 2010-06-02
ZA200800111B (en) 2008-12-31
US8921352B2 (en) 2014-12-30
DK1901736T3 (da) 2010-08-16
PL1901736T3 (pl) 2010-09-30
PT1901736E (pt) 2010-05-31
EA200702416A1 (ru) 2008-04-28
EP1901736B1 (en) 2010-04-21

Similar Documents

Publication Publication Date Title
UA90521C2 (uk) Фармацевтична композиція, що містить симвастатин і езетиміб
EA201390409A1 (ru) Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием
JP2010532765A5 (uk)
BRPI0606883A2 (pt) composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
WO2007051811A3 (en) Pharmaceutical use of substituted amides
MA33608B1 (fr) Composition pharmaceutique, forme galenique, procede pour leur preparation, methodes de traitement et leurs utilisations
MX2009009623A (es) Inidol y bencimidazol amidas como inhibidores de la dehidrogenasa hidroxi-esteroide.
WO2008076806A3 (en) Compositions and methods to potentiate colistin activity
WO2010030180A3 (en) Peptide formulations and uses thereof
MY143795A (en) Tetrahydropyridoindole derivatives
MY147373A (en) Piperazine derivatives as antimalarial agents
BR0314612A (pt) Composição farmacêutica estabilizada, contendo excipientes básicos
WO2007112000A3 (en) Treatment of pain
EP2392322A3 (en) Dosing regimes for trans-clomiphene
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
UA102187C2 (uk) Фармацевтична композиція для пероральної доставки дііндолілметану
EP2648704B1 (en) Anti-microbial composition
IL192611A0 (en) Biologically active composition comprising ethylcellulose
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
TW200736203A (en) New pleuromutilin derivative and its use
MX2013002649A (es) Agente terapeutico contra el dolor.
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
EA201290485A1 (ru) Производные бензамида
WO2007138233A3 (fr) Utilisation du zatosetron pour le traitement de la rosacee